Amicus Therapeutics, Inc. (NASDAQ:FOLD) COO Sells $105,455.42 in Stock

Amicus Therapeutics, Inc. (NASDAQ:FOLD) COO Bradley L. Campbell sold 10,514 shares of the company’s stock in a transaction dated Thursday, April 1st. The shares were sold at an average price of $10.03, for a total value of $105,455.42. Following the completion of the transaction, the chief operating officer now owns 389,371 shares in the company, valued at approximately $3,905,391.13. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Shares of FOLD stock opened at $9.37 on Thursday. Amicus Therapeutics, Inc. has a 12 month low of $8.83 and a 12 month high of $25.39. The company has a quick ratio of 5.10, a current ratio of 5.24 and a debt-to-equity ratio of 1.21. The business’s 50 day moving average is $10.72 and its two-hundred day moving average is $17.66. The company has a market cap of $2.48 billion, a PE ratio of -8.15 and a beta of 1.57.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings results on Sunday, February 28th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04). Amicus Therapeutics had a negative net margin of 120.18% and a negative return on equity of 73.81%. The company had revenue of $70.57 million for the quarter, compared to analyst estimates of $70.50 million. As a group, equities analysts expect that Amicus Therapeutics, Inc. will post -1.03 EPS for the current fiscal year.

A number of equities analysts have recently weighed in on the company. Cantor Fitzgerald downgraded Amicus Therapeutics from an “overweight” rating to a “neutral” rating and dropped their target price for the company from $30.00 to $17.00 in a report on Friday, February 12th. SVB Leerink dropped their target price on Amicus Therapeutics from $15.00 to $13.00 and set a “market perform” rating on the stock in a report on Monday, March 29th. Robert W. Baird reiterated a “buy” rating on shares of Amicus Therapeutics in a report on Wednesday, March 3rd. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell downgraded Amicus Therapeutics from a “buy” rating to a “neutral” rating and upped their target price for the company from $20.00 to $27.00 in a report on Thursday, December 10th. Finally, Citigroup dropped their price objective on Amicus Therapeutics from $27.00 to $16.00 in a report on Friday, February 12th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $19.75.

Several institutional investors and hedge funds have recently bought and sold shares of FOLD. First Trust Advisors LP bought a new stake in shares of Amicus Therapeutics in the first quarter valued at approximately $635,000. Great West Life Assurance Co. Can boosted its position in shares of Amicus Therapeutics by 34.0% in the third quarter. Great West Life Assurance Co. Can now owns 24,241 shares of the biopharmaceutical company’s stock valued at $266,000 after acquiring an additional 6,155 shares during the period. Guggenheim Capital LLC bought a new stake in shares of Amicus Therapeutics in the third quarter valued at approximately $305,000. UBS Asset Management Americas Inc. boosted its position in shares of Amicus Therapeutics by 418.2% in the third quarter. UBS Asset Management Americas Inc. now owns 1,505,578 shares of the biopharmaceutical company’s stock valued at $21,259,000 after acquiring an additional 1,215,044 shares during the period. Finally, Segall Bryant & Hamill LLC boosted its position in shares of Amicus Therapeutics by 265.2% in the third quarter. Segall Bryant & Hamill LLC now owns 188,986 shares of the biopharmaceutical company’s stock valued at $2,669,000 after acquiring an additional 137,233 shares during the period.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease.

See Also: Accumulation/Distribution

Insider Buying and Selling by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.